Download the ESMO 2012 Abstract Book - Oxford Journals

More documents

Recommendations

Info

Annals of Oncology did not modify CSS, irrespective of AC choice (interaction p for capecitabine and age = 0.26; interaction p for FOLFOX and age = 0.40). Conclusions: EPs with stage III CC frequently received either no adjuvant treatment or capecitabine monotherapy due to advanced age and comorbidities. The treatment effect of AC on CSS is similar across age groups, with comparable side effects and rates of discontinuation between EPs and YPs. AC should not be withheld from CC patients based on advanced age alone. Disclosure: All authors have declared no conflicts of interest. 602P COMPARATIVE BUDGET IMPACT ANALYSIS OF TREATMENT SEQUENCES IN METASTATIC COLORECTAL CANCER (MCRC): FROM FIRST (1ST) LINE TO THIRD (3RD) LINE THERAPIES J.A. Maroun 1 , T. Boucher 2 , K. Alloul 3 1 Medical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, CANADA, 2 Evidence Value and Access, Sanofi Canada, Montréal, QC, CANADA, 3 Health Economics and Health Outcomes, Sanofi Canada, Montreal, QC, CANADA Background: In the context of personalized cancer care, patients (pts) should receive the therapy that best meets their needs while optimizing the use of healthcare resources. A budget impact model was developed to compare each of the most commonly used mCRC treatment sequences – from 1 st line to 3rd line in a Canadian context. Methods: This Excel based model considers the price of each agent, the number of cycles per treatment course, the relative dose intensity of the regimens to determine the cost of the most commonly used mCRC therapies and calculates the costs per overall sequence from 1 st line to 3 rd line. It takes into account the percentage of pts who benefit from a R0 resection post 1 st line chemotherapy and who forego subsequent treatments. Factors such as different percentage use of 1 st line FOLFOX vs FOLFIRI and pts’ volumes per line of therapy are considered in this model. Users can choose the scenarios they would like to examine. Key variables can be extracted through expert opinion, the literature or, to assess real-world local practices, through chart reviews. Results: As scenarios considered, the budgetary impact of the 1 st line use of FOLFOX or FOLFIRI both given with bevacizumab (bev) on 1 st to 3 rd line therapy costs was assessed. The relative use of FOLFOX and FOLFIRI with bev was varied from 80% use of FOLFOX and 20% use of FOLFIRI to the opposite. As key variables, the model compares, as 1 st line therapy, 18 cycles of FOLFIRI and bev to 8 cycles of mFOLFOX6 followed by 10 cycles of 5FU/LV given with 18 cycles of bev. Also 80% of 1 st line pts receive a second line chemotherapy. Assuming a cohort of a 100 pts, when FOLFOX’s 1 st line use varies from 80% to 20%, the budget varies from $4.14M to $3.85M, with all pts undergoing a R0 resection varying from 11.8 to 8.2 pts. Conclusions: Focusing on drug costs only, this dynamic and flexible model goes beyond the comparison of upfront 1 st line mCRC costs and considers cascading costs on subsequent lines (2 nd and 3 rd line) and consequences. It can be used to assess variability in local and provincial practice patterns and their impact on overall budget costs and number of pts benefiting from a R0 resection. Disclosure: J.A. Maroun: Advisory board member for Roche and Sanofi. Involved in research projects with Roche and Sanofi. T. Boucher: Employee of Sanofi. K. Alloul: Employee of Sanofi Canada Inc. 603P FREQUENCY OF SECOND AND THIRD LINE TREATMENT AMONG ELDERLY MEDICARE STAGE 4 COLON CANCER PATIENTS C.D. Mullins 1 , K. Bikov 2 , E. Onukwugha 2 , N. Hanna 3 , B. Seal 4 1 PHSR, Univ of MD, Baltimore, MD, UNITED STATES OF AMERICA, 2 PHSR, Univ of MD, Baltimore, MD, UNITED STATES OF AMERICA, 3 Surgery, Univ of MD, Baltimore, MD, UNITED STATES OF AMERICA, 4 Health Economics and Outcomes Research, Bayer HealthCare, Wayne, NJ, UNITED STATES OF AMERICA Background: Stage 4 colon cancer (CC4) patients may receive multiple lines of chemotherapy and/or biologics as treatment (TX) to improve survival or quality of life. The tendency to use less aggressive treatment with elderly CC4 patients suggests that elderly CC4 patients may receive fewer TX lines than equivalent younger patients. Methods: Elderly (65+) SEER-Medicare patients diagnosed with CC4 in 2003-2007 were followed through death or 2009 to examine variation across sub-groups in the number of TX lines. We examined NCCN treatments that included any combination of 5-fluorouracil and/or (levo) leucovorin (5FU/LV), irinotecan (IRI), oxaliplatin (OX), and bevacizumab, cetuximab, or panitumumab (collectively identified as BIOLOGICS). Certain non-NCCN treatments were also considered as possible last TX line. A hierarchy categorized treatments as: 1) IROX (IRI + OX); 2) IRI or OX; 3) 5FU/LV; 4) BIOLOGICS without chemotherapy; and 5) other TX. Gaps in TX or changes from OX or IRI to 5FU/LV were not considered new lines. Results: Of 7,937 elderly CC4 patients, 3,263 (41%) received any TX, while 1,166 (15% of all, 36% of TX) and 244 (3% of all, 7% of TX) received second and third line TX, respectively. Fewer than 1% of treated patients had a fourth TX line. Among the TX group, relatively younger (p < 0.01), married (48 vs. 39%, p < 0.01) and urban (45 vs. 39, p = 0.04) patients were more likely to go on to second line TX. Medicare buy-in coverage, which generally indicates dual Medicaid-Medicare coverage (40 vs. 45%, p = 0.05), lowered the likelihood of second line TX. Having comorbidities impacted receipt of initial TX (CCI = 0: 44%, CCI = 1: 42%, CCI = 2: 28%; p < 0.01) and the likelihood of second (CCI = 0: 46%, CCI = 1: 42%, CCI = 2: 39%; p= 0.02) but not third TX (CCI = 0: 19%, CCI = 1: 21%, CCI = 2: 15%; p = 0.3) lines conditional upon receipt of prior line treatment. There was no significant association between second line TX and race/ethnicity or gender. There was no significant association between the examined characteristics and receipt of third line TX. Conclusions: One in three elderly CC4 patients who received initial TX received a second TX line. The likelihood of having a second TX line was associated with age, marital status, urbanicity, and comorbidity burden. Only one in fourteen elderly CC4 patients had a third TX. Disclosure: C.D. Mullins: C. Daniel Mullins, PhD receives consulting income from Amgen, Bayer, BMS, Celgene, GSK, Mitsubishi, Novartis, Novo Nordisk, Novartis, and Pfizer. He also receives research funding from Bayer and Pfizer. E. Onukwugha: Ebere Onukwugha receives consulting income from Pfizer and grant support from Bayer, Novartis, and Pfizer. B. Seal: Brian Seal is an employee of Bayer HealthCare. All other authors have declared no conflicts of interest. 604P PROGNOSTIC VALUE OF STEM CELL QUANTIFICATION IN STAGE II COLON CANCER M.A.V. Salgado 1 , J.C.M. Montero 2 , M. Devesa 1 , J.D. Trill 1 , V. Abraira 1 , A. Riquelme 3 , A. Carrato 1 1 Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, SPAIN, 2 Pathologist, Instituto Oftalmico/Hospital Universitario Gregorio Marañon, Madrid, SPAIN, 3 Medical Oncology, Hospital Infanta Cristina Parla, Madrid, SPAIN Background: Cancer stem cells (CSCs) are a subset of tumor cells with capacity to self-renew and generate the diverse cells that comprise the tumor. They are considered cancer (Ca) initiating cells responsible for tumor recurrence and maintenance. These cells express pluripotency markers (CD133 and NANOG) and do not express markers of differentiation as cytokeratin 20 (CK20). The potential prognostic value of CSCs in colorectal cancer has been studied with conflicting results. However some of these series were based on heterogeneous situations, involving rectal and colon cancer (CC) and different tumor stages (I-IV). The aim of this study is to evaluate the prognostic value of CSCs in a highly homogeneous population of stage II CC. Methods: One hundred stage II CC patients (pts) treated by the same surgical team at Ramon y Cajal University Hospital between 1977 and 2005 were retrospectively analyzed. None of the pts received adjuvant chemotherapy. Inmunohistochemistry expression of CD133, NANOG and CK20 was scored on paraffin sections using four levels: 50% positivity. Kaplan-Meier analysis and log rank test were used to compare survival. Results: Median age: 68 years (45-92). Median follow up: 5.8 years. Recurrent disease: 17 (17%). Expression of CD133 was shown in 60% of the tumors, in 95% for NANOG and 78% for CK20. No correlation was found among expression levels of CD133, NANOG or CK 20 and relapse-free survival (RFS) and overall survival (OS). Conclusions: Stem Cell quantification defined by CD133 and NANOG expression has no correlation with RFS or OS in this cohort of Stage II CC. Therefore, our results suggest that CSCs may not play a major role in early phases of CC. Disclosure: All authors have declared no conflicts of interest. 605P PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY F. Leone 1 , D. Marino 2 , S. Artale 3 , C. Cagnazzo 2 , S. Cascinu 4 , A.A. Martoni 5 , A. Sobrero 6 , M. Tampellini 7 , S. Siena 3 , M. Aglietta 8 1 Oncological Sciences, Fondazione Piemontese per la Ricerca sul Cancro Onlus, Candiolo, ITALY, 2 Medical Oncology, Fondazione Piemontese per la Ricerca sul Cancro Onlus-IRCC Institute for Cancer Research and Treatment, Candiolo, ITALY, 3 Struttura Complessa di Oncologia Falck, A.O. Ospedale Niguarda Ca’ Granda, Milano, ITALY, 4 Clinica di Oncologia Medica, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, ITALY, 5 Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna, ITALY, Bologna, ITALY, 6 Oncologia Medica, Azienda Ospedaliera Universitaria S. Martino di Genova, Genova, ITALY, 7 Dipartimento di Oncologia Medica, Azienda Ospedaliera San Luigi, Orbassano, ITALY, 8 Div Oncologia ed Ematologia, Fondazione Piemontese per la Ricerca sul Cancro Onlus, Candiolo, ITALY Background: Preoperative chemotherapy improves outcome in potentially resectable colorectal cancer with liver metastases. We evaluated the activity of a neoadiuvant treatment with capecitabine–oxaliplatin (XELOX) associated with the anti-EGFR antibody Panitumumab in patients with unresectable, liver-only, metastatic colorectal cancer (CRC). Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds397 | ix205
Patients and methods: Chemotherapy-naïve patients with unresectable liver metastases of CRC and no other metastatic sites were enrolled. Criteria of unresectability were defined as: more than3livermetastasesincluding>50% hepatic involvement and requiring a major hepatectomy with controlateral wedge resection or any metastases requiring a resection that does not preserve two contiguous hepatic segments. Since November 2008 only patients bearing wild type KRAS were included. All patients received neoadjuvant XELOX plus panitumumab (P-XELOX) and were reevaluated for resectability every four cycles. Primary endpoint was radiological objective response rate (ORR). Secondary endpoints were overall survival (OS), progression free survival (PFS), percentage of patients whose disease became radically resectable, and safety. Results: Forty-nine patients were recruited, of which 35 were KRAS wild type, and 14 (enrolled before study amendment), were unknown (9 patients) or mutated (5 patients). Forty-six were evaluable for response. Following neoadjuvant P-XELOX, the ORR in the general population was 54%, with 3 CR, 22 PR, 14 SD. In wild type KRAS patients ORR reached 65% (3 CR, 18 PR, 7 SD), and this allowed 15 patients with initial unresectable liver metastasis to be converted to resectability. Survival analysis showed median PFS and OS of 8.5 months and 22.1 months, respectively. Resected patients had significantly better OS if compared to unresected (p = 0.00014). The most common toxicities were cutaneous, gastrointestinal, and neurologic. Conclusion: Neoadjuvant P-XELOX yields high response rates for patients with metastatic CRC and extensive liver involvement, and leads to remarkable conversion to resectability of liver metastasis. Disclosure: All authors have declared no conflicts of interest. 606P BODY MASS INDEX AND IMPAIRED FASTING BLOOD GLUCOSE AS PREDICTIVE FACTORS OF EFFICACY IN CETUXIMAB-BASED COLORECTAL CANCER TREATMENT F.M. Guida1 , F. Pantano1 , E. Vasile2 , M. Rodriguez Garrote3 , E. Grande3 , N. Silvestris4 , B. Vincenzi1 , D. Santini1 , A. Falcone5 , G. Tonini1 1 2 Medical Oncology, University Campus Bio-Medico, Rome, ITALY, Oncologia, Trapianti e Nuove Tecnologie in Medicina, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, Pisa, ITALY, 3 Medical Oncology, University Hospital, Madrid, Madrid, SPAIN, 4 Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, ITALY, 5 Dept. of Oncology-Presidio Ospedaliero, Azienda Ospedaliero Univesitaria S. Chiara, Pisa, ITALY Introduction: Cetuximab is an anti-EGFR monoclonal antibody with antitumor efficacy in metastatic colorectal cancer harboring wild-type K-Ras gene. However, not all patients K-Ras wild-type benefit from Cetuximab, underscoring the need for additional markers to help in patient selection. Preclinical evidences suggest that the EGFR and Insulin-like Growth Factor-1 Receptor (IGF-1R) pathways interact to drive tumor growth and survival. It’s well known that in hyperinsulinemic state, higher insulin levels upregulate IGF-1 production, leading this state a potential biomarker for Cetuximab efficacy. The aim of our study was to evaluate the feasibility to stratify patients more likely to benefit from Cetuximab treatment using two well known signs of hyperinsulinemic state such as the high Body Mass Index (BMI) and impaired Fasting Blood Glucose (FBG). Methods: We retrospectively collected 250 K-Ras wild-type metastatic colorectal cancer patients treated with Cetuximab containing regimens in first to fifth line setting. From this cohort we selected 76 patients treated with Cetuximab + CPT11 after failure of first line CPT11 based containing regimen. We divided this population into two groups according to the presence of both elevated BMI (cut-off 24.99 sec. WHO Criteria) and high FBG (cut-off 100 mg/dL sec American Diabetes Association) and we evaluated the Time To Progression (TTP) of these two groups. Results: We found a statistically significant lower TTP in patients with both elevated BMI and FBG compared to patients with presence of none or only one of the two parameters (median TTP 4.3 months, CI95%:2.5-5.4 vs 5.6 months, CI95%:2.5-5.8; P = 0.034). Conclusions: The statistically significant poorer outcome in patients with both BMI and FBG treated with Cetuximab + CPT11 after CPT11 failure could be explained by the reduction of Cetuximab efficacy due to the probable presence of upregulation of vicar pathways such as IGF-1R linked to hyperinsulinemic state. If confirmed in larger populations and in perspective studies the hyperinsulinemic state may represent a new predictive marker of efficacy in this type of population. Disclosure: All authors have declared no conflicts of interest. Annals of Oncology 607P EFFICACY AND SAFETY OF TWO NEOADJUVANT STRATEGIES WITH BEVACIZUMAB IN LOCALLY ADVANCED RESECTABLE RECTAL CANCER: INTERIM RESULTS OF A RANDOMIZED, NON-COMPARATIVE PHASE II STUDY J. Bosset 1 , G. Mantion 2 ,T.André 3 , F. Boudghène 4 , F. Piard 5 , F. Mornex 6 , P. Maingon 7 , A. Adenis 8 , M. Piutti 9 , C. Borg 10 1 Radiotherapy, CHU Jean Minjoz, Besançon, FRANCE, 2 Service de Chirurgie Digestive Et Vasculaire, Hôpital Jean Minjoz, Besançon, FRANCE, 3 Medical Oncologie, Hôpital Saint Antoine, Paris, FRANCE, 4 Service Imagerie Médicale, Hôpital Tenon, Paris, FRANCE, 5 Service D’anatomo-pathologie, CHU de Dijon, Dijon, FRANCE, 6 Radiothérapie-oncologie, Centre Hospitalier Lyon-Sud, Lyon, FRANCE, 7 Radiothérapie, Centre Georges-François-Leclerc, Dijon, FRANCE, 8 Medical Oncology, Centre Oscar Lambret, Lille Cedex, FRANCE, 9 Responsable Etudes Cliniques, Laboratoires Roche, Boulogne-Billancourt, FRANCE, 10 Medical Oncology, Hopital Minjoz, Besançon, FRANCE Background: Current therapy of locally advanced resectable rectal cancer (LARC) involves a combination of chemotherapy (CT), radiation therapy, (RT) and total mesorectal excision (TME) surgery. Two neoadjuvant strategies with bevacizumab (Bv) were assessed in a randomized, open-label, multicentre, phase II study. Method: Patients (pts) were treated with a sequential strategy including induction Bv/6 cycles (5mg/2weeks) + Folfox4, followed by CT-RT (Bv/6 cycles + 5-FU/5 cycles) + RT(45Gy) then TME in Arm A and the same CT-RT, then TME in Arm B. Primary end-point was tumor sterilization rate (pCR) - at least 10% in each arm. Efficacy and safety were reviewed by an independent committee. Results at 8 weeks post-surgery are presented. Results: Pts characteristics in Arm A (n = 46) and in Arm B (n= 45) were: men 67%, age 60 ± 9 years, ECOG score 0 (85%), mid-rectum (60%), low-rectum (40%), MRI stage: T3N0M0/T3N1M0/T3N2M0 (20%/65%/15%). In Arm A, 94% pts completed induction and 91% had CT-RT and surgery; in Arm B 100% had CT-RT and 98% surgery. Resection was macroscopically complete in 91% pts. Median post-surgery hospitalization duration was 15 [0-84] days. In the ITT population, pCR (ypT0-N0) rate was 23.8% [12.1%-39.5%] in Arm A (p = 0.015) and 11.4% [3.8%-24.6%] in Arm B (p = 0.91), both compared to the 10% pCR initial hypothesis. Central review found similar results for pCR. At surgery and 4 weeks post-surgery grade 3/4 adverse events (AE) were reported in 10 (22%) of pts in both arms. At 8 weeks post-surgery, grade 3/4 adverse events (AE) were reported in 59% of pts in Arm A and 36% in Arm B. Grade 3/4 AEs of special interest for bevacizumab were reported in 20% of pts in Arm A and 22% in Arm B. No death was reported at 8 weeks post-surgery follow-up. Conclusions: Interim results in patients with LARC treated with 2 neoadjuvant strategies showed that bevacizumab combination to neoadjuvant CT-RT did not significantly increase pCR in Arm B. The neoadjuvant strategy assessed in Arm A seems promising and deserves further investigation. Safety was comparable in Arms A and B at 8 weeks post-surgery. Disclosure: T. André: Consultant: Roche Honoraries: Amgen, Merck, Sanofi. F. Boudghène: Honoraries : Roche. M. Piutti: Employment: Roche. All other authors have declared no conflicts of interest. 608P EXCITE: A PHASE II TRIAL OF PREOPERATIVE CETUXIMAB, IRINOTECAN AND CAPECITABINE PLUS RADIOTHERAPY (RT) IN MRI-DEFINED LOCALLY ADVANCED RECTAL CANCER (LARC) S. Gollins 1 , A.S. Myint 2 , M.P. Saunders 3 , S. Susnerwala 4 , D. Sebag-Montefiori 5 , S. Beare 6 , E. Williams 6 , N. West 7 , M. Jitlal 6 1 Clinical Oncology, North Wales Cancer Treatment Centre, Rhyl, UNITED KINGDOM, 2 Clinical Oncology, Clatterbridge Cancer Centre, Liverpool, UNITED KINGDOM, 3 Clinical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UNITED KINGDOM, 4 Clinical Oncology, Royal Preston Hospital, Preston, UNITED KINGDOM, 5 Oncology, University of Leeds, Leeds, UNITED KINGDOM, 6 CR UK & UCL Cancer Trials Centre, University College London, London, UNITED KINGDOM, 7 Pathology & Tumour Biology, University of Leeds, Leeds, UNITED KINGDOM Introduction: This phase II trial examined combining cetuximab, irinotecan and capecitabine concurrently with RT in the preoperative downstaging of LARC. Methods: Patients (pts) had rectal adenocarcinoma with locally advanced/borderline unresectable disease on MRI. KRAS/BRAF was not assessed before treatment. Pts had pelvic RT to 45 Gy in 25 daily fractions over 5 weeks with concurrent oral capecitabine at 650 mg/m 2 twice daily 5 days/week. They also received intravenous (IV) cetuximab at 400 mg/m 2 one week before RT then weekly at 250 mg/m 2 weeks 1-5 of RT plus IV irinotecan weekly at 60 mg/m 2 weeks 1-4 of RT. Surgical resection ix206 | Abstracts Volume 23 | Supplement 9 | September 2012
Page 1 and 2:
Annals of Oncology www.annonc.oxfor
Page 3 and 4:
subscriptions A subscription to Ann
Page 6 and 7:
Annals of Oncology Official Journal
Page 8 and 9:
The European Society for Medical On
Page 10 and 11:
Audit Committee Chair: Fortunato Ci
Page 12 and 13:
Familial cancer Judith Balmaña, Ba
Page 14 and 15:
ESMO 2012 Congress Travel Grants 47
Page 16 and 17:
Exhibitors The following companies
Page 18 and 19:
ESMO Fellowships, 1989-2011 The Eur
Page 20:
Ondrej Gojis, Czech Republic 2008-2
Page 23 and 24:
abstracts hpv biology and implicati
Page 25 and 26:
abstracts the characterization of l
Page 27 and 28:
abstracts description of intra-tumo
Page 29 and 30:
prevent cell death. It is anticipat
Page 31 and 32:
22IN TARGETING THE HOST IN TNBC G.
Page 33 and 34:
abstracts a paradigm shift in early
Page 35 and 36:
abstracts how can medical oncologis
Page 37 and 38:
feasibility), but by how high the c
Page 39 and 40:
abstracts re-inventing the medical
Page 41 and 42:
abstracts emerging diagnostic and t
Page 43 and 44:
abstracts biologically based treatm
Page 45 and 46:
abstracts molecular targets in mali
Page 47 and 48:
abstracts melanoma therapy: from fr
Page 49 and 50:
diagnosis and can also be used for
Page 51 and 52:
analysis at 11 months median follow
Page 53 and 54:
mouse model of Kras mutant NSCLC. I
Page 55 and 56:
abstracts subtyping soft tissue sar
Page 57 and 58:
abstracts key topics in supportive
Page 59 and 60:
ESMO-CSCO Joint Symposium: Building
Page 61 and 62:
ESMO-EANM-ESR Joint Symposium: Imag
Page 63 and 64:
ESMO-ESTRO Joint Symposium: Innovat
Page 65 and 66:
ESMO-MASCC Joint Symposium: Integra
Page 67 and 68:
ESO Society Symposium: Celebrating
Page 69 and 70:
Results: TIMP-1 expression was incr
Page 71 and 72:
will benefit from this targeted the
Page 73 and 74:
cytomegalovirus (CMV). Analysis of
Page 75 and 76:
functional consequences of Endoglin
Page 77 and 78:
elationship between the ROR score,
Page 79 and 80:
183P EPIDERMAL GROWTH FACTOR RECEPT
Page 81 and 82:
Plasma adiponectin level on the pre
Page 83 and 84:
Table: 198P PFS OS Median, mo HR Me
Page 85 and 86:
204P EVALUATION OF PTEN AND PIK3CA
Page 87 and 88:
Material and methods: We searched P
Page 89 and 90:
Results: The median concentration o
Page 91 and 92:
Table: 226P Methods: Pts were rando
Page 93 and 94:
However, additional analysis sugges
Page 95 and 96:
number of biomarkers have been trie
Page 97 and 98:
Table: 248O 249PD PROTEOMIC PREDICT
Page 99 and 100:
Conclusions: BW and serum Ctrough o
Page 101 and 102:
261P BREAST CANCER SUBTYPES AND OUT
Page 103 and 104:
90 mg/m2-cyclophophamide 600 mg/m2
Page 105 and 106:
to 9 weeks after dosing. Trastuzuma
Page 107 and 108:
Patients and methods: We reviewed d
Page 109 and 110:
sector patients. The aim of this st
Page 111 and 112:
Linear Logistic Model with Relaxed
Page 113 and 114:
Results: The median CTC fold change
Page 115 and 116:
312: Table: Chemotherapy uptake wit
Page 117 and 118:
abstracts breast cancer, locally ad
Page 119 and 120:
Results: 8 trials (2092 pts) with 1
Page 121 and 122:
absolute difference of median value
Page 123 and 124:
Novartis, Genentech, and sanofi-ave
Page 125 and 126:
Results: Three RCTs with 1023 patie
Page 127 and 128:
collected from all patients for det
Page 129 and 130:
355P FIRST REPORT OF LONG-TERM RESP
Page 131 and 132:
361P A RETROSPECTIVE ANALYSIS OF PL
Page 133 and 134:
publications and aggregated in a me
Page 135 and 136:
Thus the primary aim to target BCSC
Page 137 and 138:
383 WHY DO WOMEN WITH BREAST CANCER
Page 139 and 140:
Results: We evaluated 76 pts with M
Page 141 and 142:
more than 6 cycles of capecitabine.
Page 143 and 144:
406TiP PHASE II TRIAL OF PRIMARY SY
Page 145 and 146:
abstracts CNS tumors 410O CONDITION
Page 147 and 148:
Conclusions: Our data suggested tha
Page 149 and 150:
Conclusions: As in other cancer typ
Page 151 and 152:
432 GAMMA KNIFE RADIOSURGERY AS A M
Page 153 and 154:
abstracts developmental therapeutic
Page 155 and 156: 1PR), but no responses were seen in
Page 157 and 158: RO and Cd, as well as PD data for c
Page 159 and 160: and vulvar Ca), and 11 SDs were obs
Page 161 and 162: knowing HLA-A status double-blindly
Page 163 and 164: Acquired-resistance to EGFR inhibit
Page 165 and 166: 474P PHASE 1 STUDY OF THE SELECTIVE
Page 167 and 168: TST is active in breast and gastric
Page 169 and 170: Treatment-induced shedding of circu
Page 171 and 172: Methods: Either co-cultures of peri
Page 173 and 174: 501 PRECLINICAL DATA INVESTIGATING
Page 175 and 176: 509TiP LUX-LUNG 8: A RANDOMIZED, OP
Page 177 and 178: (P = 0.64). Synchronous BBC was sig
Page 179 and 180: abstracts gastrointestinal tumors,
Page 181 and 182: Disclosure: M. Lee: I am an employe
Page 183 and 184: plus intravenous Bev(7.5mg/kg q 21d
Page 185 and 186: anti-EGFR treatment. The present st
Page 187 and 188: patients harboring a T/T genotype t
Page 189 and 190: 551P ADJUVANT CHEMOTHERAPY (AC) USE
Page 191 and 192: experienced significantly more ≥
Page 193 and 194: functioning scales. Exploratory ana
Page 195 and 196: oxaliplatin (100 mg/m 2 )/raltitrex
Page 197 and 198: 572P PANERB STUDY: WHICH CATEGORY O
Page 199 and 200: Results: 92/114 patients were preop
Page 201 and 202: 585P CHANGES IN THE INTESTINAL ENVI
Page 203 and 204: 592P PHASE II TRIAL OF COMBINED CHE
Page 205: minutes. In a previous study, 30-mi
Page 209 and 210: 612P ARE PATIENTS WITH RESECTABLE R
Page 211 and 212: Conclusions: AMPK and ACC activatio
Page 213 and 214: of surgical monotherapy in patients
Page 215 and 216: Table: 632 633 AFLIBERCEPT/FOLFIRI
Page 217 and 218: factors play the determining role i
Page 219 and 220: Abstract withdrawn in exceptional c
Page 221 and 222: were respectively 10.6 vs 8.5 vs 3.
Page 223 and 224: Results: 20 gastrointestinal cancer
Page 225 and 226: abstracts gastrointestinal tumors,
Page 227 and 228: Day 8. A second identical course wa
Page 229 and 230: proven in stage I GC. The aim of th
Page 231 and 232: Conclusions: Longer OS to FOLFOX wa
Page 233 and 234: 692P PRELIMINARY SAFETY DATA FROM A
Page 235 and 236: subgroup. Taking into consideration
Page 237 and 238: Results: Three years of adjuvant im
Page 239 and 240: considered sufficient to give an 80
Page 241 and 242: 721P FIRST-LINE TREATMENT WITH FOLF
Page 243 and 244: after Gem-based therapy. The additi
Page 245 and 246: 735P RADIOGRAPHIC PARAMETERS IN PRE
Page 247 and 248: validate the revised AJCC 7th stagi
Page 249 and 250: Results: Among 862 MM we identified
Page 251 and 252: Results: Frequently reported advers
Page 253 and 254: gastric cancer patients with CNS me
Page 255 and 256: discriminate the prognosis of HCC p
Page 257 and 258:
prospective, non-interventional stu
Page 259 and 260:
abstracts genitourinary tumors, non
Page 261 and 262:
787O EXTERNAL VALIDATION OF THE ASS
Page 263 and 264:
patient preference for P over S, an
Page 265 and 266:
798PD OPEN-LABEL PHASE II TRIAL OF
Page 267 and 268:
Hb, PS and LM. Median PFS for patie
Page 269 and 270:
may have led to reduced dose and sh
Page 271 and 272:
Results: 1,622 patients were identi
Page 273 and 274:
RCC) was designed to address an unm
Page 275 and 276:
Patients and methods: This is a sin
Page 277 and 278:
treatment at week 4, and week 12 by
Page 279 and 280:
effective in second or further line
Page 281 and 282:
Conclusions: In pts with RCC treate
Page 283 and 284:
using Drug inCode ® pharmacogeneti
Page 285 and 286:
Table: 857P standard, but is not av
Page 287 and 288:
efused HDCT. Of 23 patients, 20 com
Page 289 and 290:
we identified 49 and 220 patients w
Page 291 and 292:
879 TREATMENT OF PATIENTS WITH META
Page 293 and 294:
Median overall survival (OS) was 26
Page 295 and 296:
abstracts Genitourinary tumors, pro
Page 297 and 298:
and week 13 BPI-SF Q3 scores), 28%
Page 299 and 300:
Working Group (PCWG)-2 guidelines r
Page 301 and 302:
atio HR 0.39; CI 0.18, 0.83, p = 0.
Page 303 and 304:
We observed tumor responses and pro
Page 305 and 306:
Here we report emerging data from t
Page 307 and 308:
928P LHRH AGONIST-INDUCED SUPPRESSI
Page 309 and 310:
Disclosure: S. Oudard: Has acted as
Page 311 and 312:
939P NEOADJUVANT SIPULEUCEL-T IN LO
Page 313 and 314:
945 BONE TURNOVER MARKERS AND POTEN
Page 315 and 316:
952 SEQUENTIAL ANDROGEN DEPRIVATION
Page 317 and 318:
managed in a multidisciplinary (MD)
Page 319 and 320:
or hypercalcemia at screening; prio
Page 321 and 322:
meeting. The prevalence of LGSC is
Page 323 and 324:
Table: 975PD Continued AMG 386 + pa
Page 325 and 326:
physicians in the U.S. and Europe.
Page 327 and 328:
989P PHASE II STUDY OF COMBINATION
Page 329 and 330:
elated with stage, nodal involvemen
Page 331 and 332:
1004P CASE CONTROL STUDY ON TWO DIF
Page 333 and 334:
eight patients who had infertility
Page 335 and 336:
abstracts head and neck cancer 1016
Page 337 and 338:
same CT/RT; Arm B2: 3 cycles of ind
Page 339 and 340:
induction chemotherapy in the treat
Page 341 and 342:
patients. We have developed a rando
Page 343 and 344:
evaluated by the screening instrume
Page 345 and 346:
morbidities that radiation would le
Page 347 and 348:
Conclusions: Through adequate selec
Page 349 and 350:
abstracts hematological malignancie
Page 351 and 352:
anthracyclines in vitro. A favorabl
Page 353 and 354:
1076P RITUXIMAB PLUS SUBCUTANEOUS C
Page 355 and 356:
than the standard target of ≥2.5
Page 357 and 358:
Patients: From November 2002 to May
Page 359 and 360:
lymphadenopathy and multiple cutane
Page 361 and 362:
prospective non-interventional stud
Page 363 and 364:
Funding: GSK Biologicals Disclosure
Page 365 and 366:
survival rates of 13-25% (Prieto et
Page 367 and 368:
high response rates and prolonged p
Page 369 and 370:
GlaxoSmithKline, Merck Sharp & Dohm
Page 371 and 372:
advisor for Merck Sharp & Dohme, an
Page 373 and 374:
or cutaneous melanoma. A survival u
Page 375 and 376:
systemic therapy or were intolerant
Page 377 and 378:
abstracts neuroendocrine tumors and
Page 379 and 380:
morbidity, with G3 tumors behaving
Page 381 and 382:
pts. Poorly differentiated endocrin
Page 383 and 384:
Adenocarcinoma was present in 25 pa
Page 385 and 386:
Method: Endobronchial ultrasound gu
Page 387 and 388:
widely used by single agent or plat
Page 389 and 390:
disease after surgery were treated
Page 391 and 392:
stage IIIA NSCLC, EML4-ALK fusion-p
Page 393 and 394:
1200P CONCOMITANT CHEMORADIATION GI
Page 395 and 396:
Patients and methods: The study was
Page 397 and 398:
months (95% CI:13-25). The PFS and
Page 399 and 400:
maintenance therapy had favourable
Page 401 and 402:
abstracts non-small cell lung cance
Page 403 and 404:
Ingelheim, GSK Biologicals (compens
Page 405 and 406:
1234PD RANDOMIZED PHASE III TRIAL O
Page 407 and 408:
GlaxoSmithKline (myself, compensate
Page 409 and 410:
1243P IDENTIFICATION OF MICRORNA (M
Page 411 and 412:
N-arm n=34 P-arm n=32 All n=66 Male
Page 413 and 414:
1255P POPULATION BASED EVALUATION O
Page 415 and 416:
1262P DISTINCT SPREAD OF EGFR MUTAT
Page 417 and 418:
1268P VISUAL DISTURBANCES IN PATIEN
Page 419 and 420:
MERCK SERONO: Advisor, speaker in s
Page 421 and 422:
Conclusions: These data from SAiL a
Page 423 and 424:
NSCLC diagnosis and time of BM diag
Page 425 and 426:
1291P PHASE I/II DOSE-FINDING STUDY
Page 427 and 428:
Network utilization of WBCGF in the
Page 429 and 430:
1303P COST EFFECTIVENESS OF PEMETRE
Page 431 and 432:
Results: The patients’ characteri
Page 433 and 434:
EGFR mut at exons 18, 19, 21, and K
Page 435 and 436:
Methods: EML4-ALK fusion was screen
Page 437 and 438:
Results: The median survival time (
Page 439 and 440:
enefit from sustained EGFR blockade
Page 441 and 442:
epresented by 19 pts (32%) female,
Page 443 and 444:
and at least one prior course of ch
Page 445 and 446:
Methods: NSCLC patients with radiog
Page 447 and 448:
1367TiP LONG-TERM ERLOTINIB THERAPY
Page 449 and 450:
Austria, Czech Republic, Finland, G
Page 451 and 452:
were every 6 weeks (wk) (S1), every
Page 453 and 454:
Advantage enrollees (83% vs. 25%) [
Page 455 and 456:
Results: Based on 10,000 simulation
Page 457 and 458:
cancer tumors 12%, Germ cell tumor
Page 459 and 460:
Material and methods: 50 lung cance
Page 461 and 462:
1414TiP IMPLEMENTATION OF CANCER RE
Page 463 and 464:
abstracts palliative care 1422O EFF
Page 465 and 466:
Method and results: A total of 317
Page 467 and 468:
1436P SURVEY ON MODELS OF INTEGRATI
Page 469 and 470:
care unit (PCU) at the National Can
Page 471 and 472:
Characteristic No. % Total 63 1 st
Page 473 and 474:
hysterectomised-9.10% and cervix ca
Page 475 and 476:
abstracts psycho-oncology 1462PD IN
Page 477 and 478:
events, tumour response, and surviv
Page 479 and 480:
abstracts sarcoma 1477O ADHESION TO
Page 481 and 482:
1481PD A PHASE II STUDY OF DOVITINI
Page 483 and 484:
1488P ORGANISATION OF SARCOMA PATIE
Page 485 and 486:
Patients and methods: From August 2
Page 487 and 488:
chemotherapy respectively. At a med
Page 489 and 490:
of this group Those with relapsed d
Page 491 and 492:
1515 PREDICTORS OF SURVIVAL IN ADOL
Page 493 and 494:
abstracts small cell lung cancer an
Page 495 and 496:
emaining receiving either CAV or to
Page 497 and 498:
1533P EXPRESSION OF WILM⍰TUMOUR G
Page 499 and 500:
more than 3 months after first line
Page 501 and 502:
lower recurrence rate of NE. Pegfil
Page 503 and 504:
egimens (HR = 2.5, p < 0.001). Phys
Page 505 and 506:
1561P PREDICTIVE DIAGNOSTICS FOR RE
Page 507 and 508:
Methods: A prospective multicentre
Page 509 and 510:
Table: 1574P Pharmacokinetic parame
Page 511 and 512:
Novartis and unrestricted research
Page 513 and 514:
studies have shown that chemotherap
Page 515 and 516:
(Grade 1) and moderate to severe (G
Page 517 and 518:
declined to relatively lower level
Page 519 and 520:
1609P PHYSICAL ACTIVITY (PA) AND PH
Page 521 and 522:
patients were admitted to the oncol
Page 523 and 524:
Dicarbamin 100 mg/day on day 5 befo
Page 525 and 526:
Results: Anemia was detected in 83.
Page 527 and 528:
important to carry out randomized s
Page 529 and 530:
abstracts translational research 16
Page 531 and 532:
expression. Then, we analyzed PB sa
Page 533 and 534:
Table: 1657P TH BV + TH HR (95% CI)
Page 535 and 536:
BRAF mutations. Circulating free DN
Page 537 and 538:
1671P PHASE I CLINICAL TRIAL OF CAN
Page 539 and 540:
1678P PREDICTIVE VALUE OF TWO PHENO
Page 541 and 542:
theorized that the PI3K/AKT pathway
Page 543 and 544:
Material and methods: 101 patients
Page 545 and 546:
overexpressing and 232 had triple n
Page 547 and 548:
author index author index A Aamdal
Page 549 and 550:
author index Badran A. ix288 (874)
Page 551 and 552:
author index Bösmüller H. ix209 (
Page 553 and 554:
author index Chen A. ix319 (966O) C
Page 555 and 556:
author index De Droogh E. ix452 (13
Page 557 and 558:
author index Esposito G. ix209 (618
Page 559 and 560:
author index Geiges G. ix306 (930P)
Page 561 and 562:
author index Hartono S. ix70 (155P)
Page 563 and 564:
author index Iwasaki H. ix542 (1694
Page 565 and 566:
author index Kodaira M. ix90 (228P)
Page 567 and 568:
author index Lichtensztejn D. ix350
Page 569 and 570:
author index Martinez A. ix496 (153
Page 571 and 572:
author index Morishita N. ix432 (13
Page 573 and 574:
author index Okamoto N. ix432 (1320
Page 575 and 576:
author index Piau S. ix456 (1401P)
Page 577 and 578:
author index Rodríguez Rodríguez
Page 579 and 580:
author index Scoggins C.R. ix371 (1
Page 581 and 582:
author index Stern L. ix272 (823P)
Page 583 and 584:
author index Trypaki M. ix429 (1308
Page 585 and 586:
author index Whitmore J.B. ix310 (9
Page 587 and 588:
subject index subject index A AAV-H
Page 589 and 590:
subject index ix115 (316TiP), ix116
Page 591 and 592:
subject index diffuse large B-cell
Page 593 and 594:
subject index (1033P), ix340 (1036P
Page 595 and 596:
subject index medical information,
Page 597 and 598:
subject index (612P), ix214 (633),
Page 599 and 600:
subject index RCC, ix274 (830P) re-
Page 601 and 602:
subject index TR-FRET, ix84 (206P)
Page 603 and 604:
drug index drug index 1248P, 1250P,
Page 605 and 606:
translational research index transl
Page 607 and 608:
Page 609:
show all

Download the ESMO 2012 Abstract Book - Oxford Journals

Create successful ePaper yourself

Delete template?

Save as template?